Streetbeat News

Revenues

PRGO

Perrigo has projected its fiscal year 2024 organic net sales growth to be between 1.0% to 3.0% year-over-year, with its reported net sales expected to remain flat. The company anticipates its adjusted earnings per share (EPS) to range from $2.50 to $2.65, which is below the consensus estimate of $3.00.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:37 am

PRGO

Perrigo announced 'Project Energize', a program to be launched in Q1 2024 aimed at driving sustainable, value accretive growth. The initiative expects to achieve annual pre-tax savings of $140M-$170M by 2026, with a portion of these savings ($40M-$60M) reinvested into the business. The restructuring will affect about 6% of Perrigo's workforce and incur charges of $140M-$160M, including investments to enhance capabilities.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:35 am

BEAM

Beam Therapeutics reported a significant increase in its Q4 earnings per share (EPS) to $1.73 from $(0.54) year-over-year, with sales reaching $316.19M, surpassing the $18.67M estimate. The company also announced a cash runway of $1.2B, expected to support its operating plans into 2027.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:34 am

XHR

Xenia Hotels & Resorts (NYSE:XHR) reported its Q4 AFFO per share as $0.41, consistent with the previous year. However, its quarterly sales of $253.38M fell short of the analyst consensus estimate of $253.79M by 0.16% and marked a 3.71% decrease from the $263.14M reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:32 am

AESI

Atlas will include Hi-Crush's financial results in its reports starting March 1, 2024, expecting sand prices to average $26-$28 per ton. With Hi-Crush's contribution, Atlas forecasts 2024 Adjusted EBITDA between $425-$475 million and capex of $335-$360 million.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:21 am

CLVT

Clarivate projects its 2024 revenues to be between $2.57B and $2.67B, below the consensus of $2.69B, and adjusted diluted EPS to range from $0.70 to $0.80, under the consensus of $0.84. The company anticipates organic growth, offset by soft transactional revenue and a small divestiture in the IP segment. Despite topline growth, investments and cost inflation are expected to contract profit margins. Capital spending will increase to about 10% of revenues for product innovation, with strong cash flow aimed at reducing debt.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:18 am

PRVA

Privia Health Group (PRVA) projects its FY24 revenue to be between $1.600B and $1.675B, significantly below the estimated $3.24B. The company plans to focus on organic provider growth, renegotiate Medicare Advantage arrangements, and exit the Delaware ACO to improve margins and increase free cash flow. Despite a projected decrease in practice collections due to these changes, PRVA expects an increase in care margin, platform contribution, and Adjusted EBITDA.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:17 am

CRI

Carter's, Inc. (CRI) forecasts low single-digit growth in net sales reaching around $3B for FY24, slightly above the $2.98B estimate. The company also anticipates mid-single-digit growth in adjusted diluted EPS.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:17 am

HSIC

Henry Schein anticipates its sales growth for the fiscal year 2024 to range between 8% to 12% over the figures reported in 2023, indicating a positive outlook for the company's financial performance in the upcoming year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:06 am

ESPR

Esperion Therapeutics reported a 44% year-over-year growth in Q4 retail prescription equivalents and projects continued momentum in this segment into the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:06 am